Targeted Oncology

🖥️Real Patient Cases Brought to You Virtually Experts in our Virtual Tumor Board series review real patient cases and inform you on the diagnosis, biomarker testing, and treatment strategies involved. 👉Watch Now: hubs.li/Q03YBNKM0

Filming in the Studio 🎥 Case-Based Peer Perspectives on bispecific therapy in relapsed/refractory multiple myeloma with @End_myeloma of @uabmedicine. Second-line decisions + where bispecifics fit for CAR-T–ineligible patients. Stay tuned. 👀

🩺 CLINICAL UPDATE: Nadofaragene firadenovec-vncg (Adstiladrin) received an upgraded #NCCN category 2A recommendation for patients with papillary tumors without CIS, while maintaining its category 2A recommendation for patients with CIS. #BladderCancer hubs.li/Q047JN870

🔬 Real-world brexu-cel CAR-T data in adult R/R B-ALL show trial-like ICANS, CRS, and highlight monitoring and risk factors. #CARTTherapy #Leukemia #RWD hubs.li/Q047HcT90

📢 BREAKING: The #FDA approves nivolumab with AVD for Hodgkin #lymphoma, showing superior survival rates and reduced toxicity compared to existing treatments. hubs.ly/Q047L9m90

📹 WATCH: Erica Pimenta, MD, PhD (@DanaFarber) discusses her research into using existing GLP-1 receptor agonists in dedifferentiated #liposarcoma. #Sarcoma hubs.li/Q047Hd-g0

🔬 Phase 2 data show one-time liso-cel CAR T delivers 95% responses in hard-to-treat marginal zone #lymphoma, with low severe CRS and neurotoxicity. #MZL hubs.li/Q047H5BN0

#Lymphoma care still leaves gaps—and research aims for higher cure rates, longer remission, and fewer toxicities across B-, T-cell and Hodgkin. 📹 Dr Matthew Matasar (@RutgersCancer) highlights these efforts with us in a recent interview: hubs.li/Q047H8H-0

📹 WATCH: In this episode of The OncoloGIST, Dr Paolo Tarantino (@DanaFarber) discusses how ADCs are revolutionizing #BreastCancer care, expanding beyond HER2-positive to HER2-low tumors—and spotlighting MRD testing as the next frontier. @PTarantinoMD hubs.li/Q047H9qC0

@VictoriaRizkMD explains how genomic assays guide adjuvant therapy in HR-positive, HER2-negative #breastcancer, clarifying who benefits from chemo by age, nodal status, and risk score. targetedonc.com/view/optimizin…

🎥WATCH: Matthew J. Matasar, MD (@RutgersCancer) discusses #lymphoma care shifts beyond harsh chemo as CAR T, bispecific antibodies, and antibody-drug conjugates deliver stronger, safer treatment.🧑‍🔬 targetedonc.com/view/navigatin…

🚨FDA News: FDA grants orphan drug status to irinotecan ChemoSeed implant for high-grade gliomas, enabling sustained local brain tumor therapy and accelerating pivotal trials. #oncologynews targetedonc.com/view/fda-grant…

🎥WATCH: Rutika Mehta, MD, MPH (@rutikamehtaMD) discusses how ctDNA/MRD testing guides gastroesophageal cancer care—patient counseling, coverage hurdles, and what rising #ctDNA means before scans. targetedonc.com/view/ctdna-in-…

💡Early results from TALAPRO-3 suggest that the combination of talazoparib and enzalutamide may redefine the treatment paradigm for HRR gene-mutated #mCSPC targetedonc.com/view/talazopar…

🎥WATCH: Luciano Costa, MD, PhD, (@End_myeloma) discusses the considerations for managing infection risk with bispecific antibodies in #multiplemyeloma. targetedonc.com/view/managing-…

Luciano Costa, MD, PhD (@End_myeloma) discusses the recent FDA approval of teclistamab (Tecvayli) and daratumumab and hyaluronidase-fihj (Darzelex Faspro) for patients with #myeloma 🔗: targetedonc.com/view/approval-…

📲 Your next oncology event is just 2 steps away. Sign up for Targeted Oncology™ text alerts and get invitations delivered straight to your phone. Easy. Fast. Direct. 👉 Sign up now: hubs.li/Q03_Yqj10

📹 WATCH: Vincent Ma, MD (@UWCarbone) discusses the next steps in proving the value of circulating tumor DNA in predicting outcomes of advanced #melanoma treatment. @VincentMaMD hubs.li/Q047jtt50

🔎 The #FDA clears MyChoice CDx to find HRD-positive advanced #OvarianCancer patients for niraparib, using BRCA and genomic instability testing. hubs.li/Q047rtDY0

🔬 A real-world analysis of patients with #myeloma receiving teclistamab prior to 2022 showed comparable outcomes to clinical trials and indicated adoption of proactive adverse event management. hubs.li/Q047jnJf0